ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505

Also written as “B1962” and “AP505”.

Its studies are mostly in Colorectal Neoplasms · Triple Negative Breast Neoplasms · Neoplasms, led by 2 companies.

Drug pageAnti-PD-L1/Anti-VEGF Bispecific Antibody AP505: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 28, 20244 company-led studies, 4 open or runningNext primary completion: Jan 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Groupits history only33 open or runningphase 2since Nov 28, 2024Nov 9, 2022Jan 1, 2027phase 2 · NCT06838546
AP Biosciencesits history only11 open or runningphase 1since Nov 22, 2024Nov 22, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2022First study: phase 1 study in NeoplasmsNew to China Resources Pharmaceutical GroupChina Resources Pharmaceutical Group · NCT05650385 · 68 planned · China
  2. Nov 22, 2024AP Biosciences’ first study: phase 1 study in Advanced Solid TumorsNew to AP BiosciencesAP Biosciences · NCT06723964 · 35 enrolled · Taiwan
  3. Nov 28, 2024Phase 2 study in Triple Negative Breast NeoplasmsChina Resources Pharmaceutical Group · NCT06724263 · 120 planned · China
  4. Feb 17, 2025Phase 2 study in Advanced Colorectal CancerChina Resources Pharmaceutical Group · NCT06838546 · 80 planned · China

Ahead

  1. Jan 1, 2027Primary completion: phase 2 study in Advanced Colorectal CancerChina Resources Pharmaceutical Group · NCT06838546

TargetBeta

CD274 →read by rule
“A bispecific antibody composed of an immunoglobulin G1 (IgG1) monoclonal antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06838546Advanced Colorectal Cancer · China2Not yet recruitingChina Resources Pharmaceutical GroupJan 1, 202780
NCT06724263Triple Negative Breast Neoplasms · China2Not yet recruitingChina Resources Pharmaceutical GroupAug 2026120
NCT06723964Advanced Solid Tumors · Taiwan1Active, not recruitingAP BiosciencesOct 31, 202435
NCT05650385Neoplasms · China1Not yet recruitingChina Resources Pharmaceutical GroupDec 202368

How it is read

Names in the registry

  • “B1962”, 3 entries
  • “AP505”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.